KemPharm (NASDAQ:KMPH) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, March 9th.
A number of other equities analysts have also commented on the company. Oppenheimer set a $13.00 price objective on KemPharm and gave the stock a “buy” rating in a research note on Sunday, February 25th. Canaccord Genuity set a $11.00 price objective on KemPharm and gave the company a “buy” rating in a report on Friday, February 23rd. Royal Bank of Canada set a $9.00 price objective on KemPharm and gave the company a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $9.95.
NASDAQ KMPH traded down $1.10 during trading on Friday, hitting $6.80. The company’s stock had a trading volume of 246,708 shares, compared to its average volume of 181,653. The company has a market cap of $115.79, a P/E ratio of -2.30 and a beta of -0.36. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. KemPharm has a 52 week low of $2.45 and a 52 week high of $8.40.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Thursday, March 29th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.04). sell-side analysts expect that KemPharm will post -2.23 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of KMPH. Victory Capital Management Inc. boosted its position in KemPharm by 26.7% during the fourth quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after purchasing an additional 34,114 shares during the last quarter. C WorldWide Group Holding A S boosted its position in KemPharm by 14.1% during the third quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after purchasing an additional 53,829 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its position in KemPharm by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after purchasing an additional 17,721 shares during the last quarter. 36.56% of the stock is owned by hedge funds and other institutional investors.
KemPharm Company Profile
KemPharm, Inc, a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.